Genomic Health, Inc. (NASDAQ:GHDX) – William Blair lowered their FY2017 earnings per share estimates for Genomic Health in a research note issued on Monday. William Blair analyst A. Murphy now expects that the medical research company will post earnings per share of ($0.09) for the year, down from their prior estimate of $0.01. William Blair also issued estimates for Genomic Health’s FY2019 earnings at $0.65 EPS.

ILLEGAL ACTIVITY NOTICE: “FY2017 EPS Estimates for Genomic Health, Inc. Reduced by Analyst (GHDX)” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.watchlistnews.com/fy2017-eps-estimates-for-genomic-health-inc-reduced-by-analyst-ghdx/1706004.html.

Other research analysts also recently issued research reports about the stock. Canaccord Genuity restated a “buy” rating and issued a $39.00 price target on shares of Genomic Health in a research report on Wednesday. Jefferies Group LLC restated a “hold” rating and issued a $33.00 price target on shares of Genomic Health in a research report on Thursday, September 14th. Cowen and Company restated a “hold” rating and issued a $34.00 price target on shares of Genomic Health in a research report on Friday, September 1st. BidaskClub upgraded shares of Genomic Health from a “sell” rating to a “hold” rating in a research report on Saturday, August 26th. Finally, Piper Jaffray Companies reiterated a “hold” rating and set a $31.00 target price on shares of Genomic Health in a research report on Thursday, August 3rd. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and one has issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $32.67.

Genomic Health (GHDX) opened at $28.61 on Wednesday. Genomic Health has a 1 year low of $26.37 and a 1 year high of $34.02.

Several hedge funds and other institutional investors have recently bought and sold shares of GHDX. Cubist Systematic Strategies LLC bought a new stake in shares of Genomic Health in the 3rd quarter worth $138,000. Dubuque Bank & Trust Co. grew its stake in shares of Genomic Health by 8.4% in the 2nd quarter. Dubuque Bank & Trust Co. now owns 4,897 shares of the medical research company’s stock worth $159,000 after acquiring an additional 379 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Genomic Health by 48.7% in the 1st quarter. Legal & General Group Plc now owns 6,222 shares of the medical research company’s stock worth $196,000 after acquiring an additional 2,038 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Genomic Health by 37.8% in the 2nd quarter. SG Americas Securities LLC now owns 6,122 shares of the medical research company’s stock worth $199,000 after acquiring an additional 1,679 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Genomic Health in the 3rd quarter worth $227,000. Hedge funds and other institutional investors own 89.13% of the company’s stock.

In other Genomic Health news, insider James J. Vaughn sold 1,379 shares of the company’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $32.51, for a total transaction of $44,831.29. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Kimberly J. Popovits sold 5,000 shares of the company’s stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $31.00, for a total transaction of $155,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 21,379 shares of company stock worth $676,131 in the last quarter. 46.20% of the stock is owned by corporate insiders.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Earnings History and Estimates for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.